KR102122416B1 - 세포독성 디펩티드의 동결건조 제제 - Google Patents

세포독성 디펩티드의 동결건조 제제 Download PDF

Info

Publication number
KR102122416B1
KR102122416B1 KR1020177035122A KR20177035122A KR102122416B1 KR 102122416 B1 KR102122416 B1 KR 102122416B1 KR 1020177035122 A KR1020177035122 A KR 1020177035122A KR 20177035122 A KR20177035122 A KR 20177035122A KR 102122416 B1 KR102122416 B1 KR 102122416B1
Authority
KR
South Korea
Prior art keywords
melphalan flufenamide
cyclodextrin
solution
lyophilized
melphalan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177035122A
Other languages
English (en)
Korean (ko)
Other versions
KR20170140409A (ko
Inventor
잭 스피라
프레드릭 레만
Original Assignee
온코펩타이드즈 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코펩타이드즈 아베 filed Critical 온코펩타이드즈 아베
Publication of KR20170140409A publication Critical patent/KR20170140409A/ko
Application granted granted Critical
Publication of KR102122416B1 publication Critical patent/KR102122416B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020177035122A 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제 Active KR102122416B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1150371 2011-04-28
SE1150371-1 2011-04-28
US201161535126P 2011-09-15 2011-09-15
US61/535,126 2011-09-15
PCT/EP2012/057577 WO2012146625A1 (en) 2011-04-28 2012-04-25 Lyophilized preparation of cytotoxic dipeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137031096A Division KR101808895B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020207016300A Division KR102194376B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제
KR1020207003073A Division KR102122429B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제

Publications (2)

Publication Number Publication Date
KR20170140409A KR20170140409A (ko) 2017-12-20
KR102122416B1 true KR102122416B1 (ko) 2020-06-12

Family

ID=47071620

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177035122A Active KR102122416B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제
KR1020137031096A Active KR101808895B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137031096A Active KR101808895B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제

Country Status (29)

Country Link
US (8) US20140128462A1 (enExample)
EP (4) EP3228319B1 (enExample)
JP (1) JP6042412B2 (enExample)
KR (2) KR102122416B1 (enExample)
CN (2) CN108096563A (enExample)
AU (1) AU2012247545B2 (enExample)
BR (2) BR122019017088B1 (enExample)
CA (2) CA3024230C (enExample)
CY (2) CY1119453T1 (enExample)
DK (3) DK3656393T3 (enExample)
ES (2) ES2930140T3 (enExample)
FI (1) FIC20230004I1 (enExample)
FR (1) FR23C1000I2 (enExample)
HR (2) HRP20171523T1 (enExample)
HU (3) HUE060783T2 (enExample)
IL (3) IL228889A0 (enExample)
LT (3) LT3656393T (enExample)
LU (1) LUC00291I2 (enExample)
MX (1) MX345102B (enExample)
NL (1) NL301206I2 (enExample)
NO (1) NO2023004I1 (enExample)
PL (3) PL2701720T3 (enExample)
PT (2) PT2701720T (enExample)
RS (3) RS56462B1 (enExample)
RU (1) RU2597154C2 (enExample)
SI (2) SI2701720T1 (enExample)
SM (3) SMT202000447T1 (enExample)
WO (1) WO2012146625A1 (enExample)
ZA (1) ZA201308765B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56462B1 (sr) 2011-04-28 2018-01-31 Oncopeptides Ab Liofilizovani preparat citotoksičnih dipeptida
JP5827178B2 (ja) * 2012-06-05 2015-12-02 北越紀州製紙株式会社 セルロース多孔質体及びその製造方法
JP6284945B2 (ja) * 2012-10-26 2018-02-28 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ メルファランフルフェナミドの凍結乾燥製剤
DK2928463T3 (da) * 2012-10-26 2020-02-24 Oncopeptides Ab Lyofiliserede præparater af melphalan-flufenamid
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
US10369077B2 (en) * 2017-05-31 2019-08-06 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using the same
US10507165B2 (en) 2017-05-31 2019-12-17 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using same
AU2019362389B2 (en) * 2018-10-18 2024-12-12 Oncopeptides Innovation Ab Compounds containing deuterium
CN114025753A (zh) 2019-04-03 2022-02-08 肿瘤多肽有限公司 用美氟芬治疗al淀粉样变性
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
WO2021226566A1 (en) * 2020-05-08 2021-11-11 Cjb Applied Technologies, Llc Pesticidal compositions and related methods
AU2021327164A1 (en) * 2020-08-19 2023-03-16 Cellact Pharma Gmbh Etoposide toniribate formulation
US12077809B2 (en) 2021-04-27 2024-09-03 Enplas Corporation Freeze-dried structure and producing method thereof
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
EP4366721A1 (en) 2021-07-08 2024-05-15 Oncopeptides Innovation AB Melflufen for use in the treatment of multiple myeloma
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
KR102757193B1 (ko) * 2021-10-19 2025-01-21 단국대학교 천안캠퍼스 산학협력단 피리미딘-2,4-다이온 유도체를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096367A1 (en) * 2000-06-13 2001-12-20 Oncopeptides Ab Melphalan derivatives and their use as cancer chemotherapeutic drugs
US20040034099A1 (en) 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US20040097421A1 (en) 2000-06-13 2004-05-20 Rolf Lewensohn Melphalan derivatives and their use as cancer chemotherapeutic drugs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
JP3176716B2 (ja) 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
RU2279292C2 (ru) 2001-10-24 2006-07-10 Пари Гмбх Набор для приготовления фармацевтической композиции
NZ534378A (en) * 2002-02-22 2006-10-27 Schering Corp Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US7632491B2 (en) 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
NZ554761A (en) * 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
HRP20090078A2 (en) 2006-07-07 2009-06-30 Gilead Sciences Novel pyridazine compound and use thereof
JP2010510327A (ja) 2006-11-21 2010-04-02 ジャイナ ファーマシューティカルズ，インコーポレーテッド エンドキシフェンの方法および組成物
CN101584669B (zh) * 2009-06-19 2010-12-29 江苏奥赛康药业有限公司 美法仑冻干粉针剂
WO2011078782A1 (en) * 2009-12-22 2011-06-30 Oncopeptides Ab A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
SI2696848T1 (sl) * 2011-04-15 2020-10-30 Janssen Pharmaceutica N.V. Liofilizirane zdravilne nanosuspenzije
RS56462B1 (sr) 2011-04-28 2018-01-31 Oncopeptides Ab Liofilizovani preparat citotoksičnih dipeptida
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ メルファランフルフェナミドの凍結乾燥製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096367A1 (en) * 2000-06-13 2001-12-20 Oncopeptides Ab Melphalan derivatives and their use as cancer chemotherapeutic drugs
US20040097421A1 (en) 2000-06-13 2004-05-20 Rolf Lewensohn Melphalan derivatives and their use as cancer chemotherapeutic drugs
US20040034099A1 (en) 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Excipients and Food Chem. 1(1), 2010, 41-54

Also Published As

Publication number Publication date
LUC00291I2 (enExample) 2025-05-12
KR20170140409A (ko) 2017-12-20
US11896668B2 (en) 2024-02-13
SI3228319T1 (sl) 2020-10-30
CA3024230C (en) 2022-10-18
LT2701720T (lt) 2017-11-10
CY1123242T1 (el) 2021-10-29
CY1119453T1 (el) 2018-03-07
ES2930140T3 (es) 2022-12-07
PL3228319T3 (pl) 2021-02-08
US20170049894A1 (en) 2017-02-23
NL301206I1 (en) 2022-12-14
US10869928B2 (en) 2020-12-22
US20140128462A1 (en) 2014-05-08
RS60719B1 (sr) 2020-09-30
MX2013012545A (es) 2014-04-16
HRP20171523T1 (hr) 2017-11-17
SMT201700459T1 (it) 2017-11-15
LTC2701720I2 (enExample) 2024-09-25
IL265457A (en) 2019-05-30
PT3656393T (pt) 2022-11-03
IL272429A (en) 2020-03-31
US20200345848A1 (en) 2020-11-05
NO2023004I1 (no) 2023-01-16
RU2013152751A (ru) 2015-06-10
IL265457B (en) 2021-02-28
RS63747B1 (sr) 2022-12-30
NZ617197A (en) 2015-06-26
PL3656393T3 (pl) 2023-01-16
CA3024230A1 (en) 2012-11-01
BR112013027584B1 (pt) 2020-11-03
KR101808895B1 (ko) 2017-12-13
NL301206I2 (nl) 2023-01-24
CA2833500C (en) 2019-01-08
AU2012247545B2 (en) 2016-08-11
FR23C1000I2 (fr) 2024-03-15
FR23C1000I1 (fr) 2023-03-10
ES2642676T3 (es) 2017-11-17
JP2014512402A (ja) 2014-05-22
EP3228319B1 (en) 2020-06-03
US10322182B2 (en) 2019-06-18
BR122019017088B1 (pt) 2021-11-16
LT3656393T (lt) 2022-12-12
EP3656393B1 (en) 2022-08-24
KR20140041497A (ko) 2014-04-04
ZA201308765B (en) 2016-02-24
US20200121794A1 (en) 2020-04-23
US20190240332A1 (en) 2019-08-08
US20240358838A1 (en) 2024-10-31
US20200009252A1 (en) 2020-01-09
DK3656393T3 (da) 2022-11-14
EP4122482A1 (en) 2023-01-25
CA2833500A1 (en) 2012-11-01
HRP20221355T1 (hr) 2022-12-23
PL2701720T3 (pl) 2017-12-29
EP3656393A1 (en) 2020-05-27
CN108096563A (zh) 2018-06-01
US20220323585A1 (en) 2022-10-13
IL228889A0 (en) 2013-12-31
EP2701720B1 (en) 2017-07-12
CN103547279A (zh) 2014-01-29
RU2597154C2 (ru) 2016-09-10
WO2012146625A1 (en) 2012-11-01
BR112013027584A2 (pt) 2016-09-06
HUS2300005I1 (hu) 2023-02-28
DK2701720T3 (en) 2017-10-09
HUE037863T2 (hu) 2018-09-28
SI2701720T1 (sl) 2017-11-30
IL272429B (en) 2022-05-01
DK3228319T3 (da) 2020-09-07
MX345102B (es) 2017-01-16
PT2701720T (pt) 2017-10-20
AU2012247545A1 (en) 2013-10-31
SMT202000447T1 (it) 2020-09-10
JP6042412B2 (ja) 2016-12-14
EP2701720A1 (en) 2014-03-05
US11344622B2 (en) 2022-05-31
FIC20230004I1 (fi) 2023-01-19
US10543274B2 (en) 2020-01-28
SMT202200450T1 (it) 2023-01-13
HUE060783T2 (hu) 2023-04-28
EP3228319A1 (en) 2017-10-11
RS56462B1 (sr) 2018-01-31

Similar Documents

Publication Publication Date Title
KR102122416B1 (ko) 세포독성 디펩티드의 동결건조 제제
KR102122429B1 (ko) 세포독성 디펩티드의 동결건조 제제
HK40081253A (en) Lyophilized preparation of cytotoxic dipeptides
HK40018864B (en) Lyophilized preparation of cytotoxic dipeptides
HK40018864A (en) Lyophilized preparation of cytotoxic dipeptides
HK1245124B (en) Lyophilized preparation of cytotoxic dipeptides
HK1245124A1 (en) Lyophilized preparation of cytotoxic dipeptides
NZ617197B2 (en) Lyophilized preparation of cytotoxic dipeptides

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171205

Application number text: 1020137031096

Filing date: 20131122

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181029

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190826

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200306

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200608

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200609

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240430

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250403

Start annual number: 6

End annual number: 6